REQUEST FOR INFORMATION
Use the form below to submit your request for information to Altasciences.
The devotion, expertise, and degree of professionalism employed by the (Altasciences) team in all stages of development, and the support provided during the Clinical trial, were unprecedented.
Read the Blog
February 20, 2020
Choosing the right CRO as a partner for your drug development programs is a vitally important step to achieving critical decision making early on for important milestones, and ultimately getting your molecule from discovery to market efficiently.
Related Press Release
Mar 27, 2020
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).
Safety assessments for both small and large molecules
Clinical pharmacology trials from first-in-human to end of Phase II
As part of our full service offering or as standalone solutions
From formulation development, phase I through commercial manufacturing, and ICH stability testing
We have received your message and will contact you shortly.